Advancing RAS-Targeted Drug Development with Ultra-Deep Genomics, Personalized MRD, and Multi-Omic Resistance Monitoring

• Advancing from standard to ultra-deep ctDNA molecular profiling to expand patient identification and enrollment, enable therapy response monitoring, support global clinical trials, and accelerate the next-generation CDx assay development
• Applying personalized, clinically actionable MRD assay to monitor molecular response, detect residual disease, and identify emerging RAS-pathway resistance mechanisms
• Expanding beyond genomics through epigenomic and transcriptomic liquid biopsy approaches to provide functional insights into tumor biology, therapy response, and rational combination treatment strategies

Speakers:

Myles Walsh

Executive Director, Business Development

Predicine